Overview

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

Status:
Enrolling by invitation
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
Phase:
Phase 3
Details
Lead Sponsor:
Braintree Laboratories